- Patients who were diagnosed as mild or moderate in severity by the classification of
infection of the Japanese Society of Chemotherapy guidelines for the evaluation
methods of new antibacterial drug (established in 1997).
- Severe underlying disease; patients in which drug clinical evaluation is difficult
because of confounding diseases.